Cite
HARVARD Citation
Richardson, D. et al. (n.d.). TP037/#453 Up-next (GOG-3049/ENGOT-OV71-NSGO-CTU): a study of upifitamab rilsodotin (UPRI), a NaPi2b -directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer. International journal of gynecological cancer. p. A241. [Online].